Adverse Event Reports Rising, FDA Staffing Levels Not Keeping Pace
This article was originally published in The Pink Sheet Daily
Adverse event reports per year have quadrupled over the last decade, and FDA expects the reports to retain their importance even as new technology helps with drug safety monitoring.
You may also be interested in...
“Expedited Agency Review” idea would require an FDA review of proposed safety-related labeling changes before they are made and end the CBE-0 system brand companies already use and generics could be required to adopt.
Agency seeks academic institutions and commercial organizations with tools that can conduct automated analysis of case reports from FAERS data.
Pilot project for overactive bladder drug Mybretriq raises questions as to how Sentinel will affect sponsor’s risk-monitoring obligations.